<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We report an adult case of reactive <z:mpath ids='MPATH_654'>hemophagocytic syndrome</z:mpath> (RHS) associated with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) who received emergency bone marrow transplantation (BMT) </plain></SENT>
<SENT sid="1" pm="."><plain>Despite <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> pulse therapy, high-dose gamma-globulin, and chemotherapy containing <z:chebi fb="0" ids="4911">etoposide</z:chebi>, the <z:hpo ids='HP_0001876'>pancytopenia</z:hpo> progressed </plain></SENT>
<SENT sid="2" pm="."><plain>After informed consent, the patient underwent syngeneic BMT using melphalan as the conditioning regimen </plain></SENT>
<SENT sid="3" pm="."><plain>The patient has been well without relapse of RHS and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> for more than 2 years after BMT </plain></SENT>
<SENT sid="4" pm="."><plain>This result suggests that the above strategy, including BMT, should be considered for the treatment of adult RHS associated with <z:e sem="disease" ids="C0848852,C0376545" disease_type="Neoplastic Process" abbrv="">hematological malignancy</z:e> </plain></SENT>
</text></document>